By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SNY.FR, SNY) on Friday said a Phase 2 proof-of-concept study of the investigational antibody REGN3500 in asthma met its primary and a key secondary endpoint.
The companies said REGN3500 as a monotherapy significantly reduced loss of asthma control and improved lung function compared with placebo.
REGN3500 inhibits interleukin-33, a protein that is believed to play a key role in type 1 and type 2 inflammation, the companies said. The antibody was invented using Regeneron's VelocImmune technology and is being developed jointly by Regeneron and Sanofi as part of a long-running collaboration.
Regeneron, based in Tarrytown, N.Y., and France's Sanofi are studying REGN3500 in Phase 2 trials for asthma, chronic obstructive pulmonary disease and atopic dermatitis--diseases where inflammation is thought to play an underlying role.
The companies jointly market Dupixent, an antibody that inhibits two other proteins and is approved in indications for asthma and atopic dermatitis, or eczema.
Write to Colin Kellaher at email@example.com